Breast Cancer Articles

Optimizing HER2-Targeted Therapy
Sara Hurvitz, MD, and Sunil Verma, MD, share their expert insight on the latest groundbreaking developments in HER2-positive breast cancer.
An Early Voice for Breast Conservation Therapy Reflects on a Changing Field
As a trailblazer who helped breast cancer treatment evolve from radical mastectomy to the judicious use of radiation therapy with limited tumor removal, Samuel Hellman, MD, is considered one of the world's premier radiation oncologists.
Acquired HER2 mutations cause endocrine resistance in some patients with ER+/HER2-negative breast cancer.
HR-Positive Advances Highlight the Good News in Breast Cancer
Recent advancements in the field of breast cancer are reshaping the treatment paradigm for subsets of patients with the disease, bringing new therapies and strategies into focus.
The rate of resection of primary breast cancer in the setting of distant metastatic disease has fallen dramatically over the past decade, but results from recent studies may alter this trend.
Employing preclinical detection using bioimpedance spectroscopy, breast centers are reporting progression to clinical lymphedema in less than 10% of patients at high risk of developing the condition.
Hospitalists and Nonphysician Providers Can Step Into the Breach
Andrew Seidman, MD, focuses on his view of the increasing role of nurse practitioners in the outpatient setting and hospitalists in the inpatient setting.
Looking for a Therapeutic Edge Among CDK Inhibitors
Whenever 3 agents joining the therapeutic armamentarium do so for similar indications with essentially identical mechanisms of action, it is reasonable to ask whether these agents have specific differences that might help decide which to use.
Testing the Power of Neoadjuvant Systemic Therapy in Breast Cancer
Neoadjuvant therapy can eliminate both invasive and in situ carcinoma in up to 50% of patients, particularly when their subtypes are triple-negative disease or HER2-positive cancers.
Abemaciclib Data Reviewed as New Breast Cancer Indications Added
Abemaciclib (Verzenio) has quickly amassed several clinical indications for patients with metastatic breast cancer, and is the only CDK4/6 inhibitor approved as a single agent.
Publication Bottom Border
Border Publication